The Day After Tomorrow – The Drug Pricing Transparency Chorus Grows Louder

This article examines the current state and what the future may hold. Breaking with the tradition of past Food and Drug Administration (“FDA”) heads, Dr. Scott Gottlieb continues to speak out on drug pricing and competition; topics usually considered outside of the Commissioner’s purview. However, Dr. Gottlieb is not alone. The chorus of advocates calling for transparency in drug pricing transparency has rapidly grown from citizen activists and academics to legislators at all levels of government and now the FDA Commissioner. What is remarkable is the uniformity of their reasoning why transparency is necessary and the disparity of their ideas of what drug pricing transparency looks like. To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In       Related StoriesOregon: Transparency’s Latest FrontierSenate Holds Hearing on 340B Drug Pricing ProgramHigher Outpatient Drug Spending At 340B Hospitals, According to New Analysis 
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs